Literature DB >> 18032995

Quality of life utilities for pelvic inflammatory disease health states.

Kenneth J Smith1, Joel Tsevat, Roberta B Ness, Harold C Wiesenfeld, Mark S Roberts.   

Abstract

PURPOSE: Quality of life utilities for health states associated with pelvic inflammatory disease (PID) have been estimated but not directly measured. Utilities for PID could have important implications on the cost-effectiveness of interventions to prevent and manage this disease.
METHODS: We obtained, in women with versus without a history of PID, visual analogue scale (VAS) and time-tradeoff (TTO) valuations for 5 PID-associated health states: ambulatory PID treatment, hospital PID treatment, ectopic pregnancy, chronic pelvic pain, and infertility. Subjects read brief scenarios describing the medical, functional, and social activity effects typically associated with each state, then gave valuations in the order above.
RESULTS: Health state valuations were obtained from 56 women with and 150 women without a PID history. Subjects with a PID history had significantly lower mean valuations (P <0.05) on the VAS for ectopic pregnancy (0.55 vs. 0.63), pelvic pain (0.45 vs. 0.53), and infertility (0.53 vs. 0.66) but not on the TTO; VAS differences remained significant when controlling for demographic and childbearing characteristics. VAS and TTO valuations were similar in women with versus without a history of PID for the ambulatory and hospital PID treatment health states.
CONCLUSION: PID has substantial impact on utility. In addition, some PID-related health states are valued less by women who have experienced PID, which could affect cost-effectiveness analyses of PID treatments when examined from the societal versus patient perspective.

Entities:  

Mesh:

Year:  2008        PMID: 18032995     DOI: 10.1097/OLQ.0b013e31815b07dd

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  11 in total

1.  Measuring health utility in varying pregnancy contexts among a diverse cohort of pregnant women.

Authors:  Lisbet S Lundsberg; Xiao Xu; Eleanor B Schwarz; Aileen M Gariepy
Journal:  Contraception       Date:  2017-08-17       Impact factor: 3.375

Review 2.  Developing a Public Health Response to Mycoplasma genitalium.

Authors:  Matthew R Golden; Kimberly A Workowski; Gail Bolan
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

3.  The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.

Authors:  Akila Subramaniam; Brett D Einerson; Christina T Blanchard; Britt K Erickson; Jeff Szychowski; Charles A Leath; Joseph R Biggio; Warner K Huh
Journal:  Gynecol Oncol       Date:  2018-11-23       Impact factor: 5.482

4.  An economic model of school-based behavioral interventions to prevent sexually transmitted infections.

Authors:  Keith Cooper; Jonathan Shepherd; Jo Picot; Jeremy Jones; Josephine Kavanagh; Angela Harden; Elaine Barnett-Page; Andrew Clegg; Debbie Hartwell; Geoff Frampton; Alison Price
Journal:  Int J Technol Assess Health Care       Date:  2012-09-21       Impact factor: 2.188

5.  Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S.

Authors:  Kwame Owusu-Edusei; Karen W Hoover; Thomas L Gift
Journal:  Am J Prev Med       Date:  2016-03-04       Impact factor: 5.043

6.  Impact and cost-effectiveness of chlamydia testing in Scotland: a mathematical modelling study.

Authors:  Katharine J Looker; Lesley A Wallace; Katherine M E Turner
Journal:  Theor Biol Med Model       Date:  2015-01-15       Impact factor: 2.432

7.  Recommendation on screening for chlamydia and gonorrhea in primary care for individuals not known to be at high risk.

Authors:  Ainsley Moore; Gregory Traversy; Donna L Reynolds; John J Riva; Guylène Thériault; Brenda J Wilson; Melissa Subnath; Brett D Thombs
Journal:  CMAJ       Date:  2021-04-19       Impact factor: 8.262

8.  An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England.

Authors:  Katherine M E Turner; Jeff Round; Patrick Horner; John Macleod; Simon Goldenberg; Arminder Deol; Elisabeth J Adams
Journal:  Sex Transm Infect       Date:  2013-11-22       Impact factor: 3.519

9.  Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees.

Authors:  Susie E Huntington; Richéal M Burns; Emma Harding-Esch; Michael J Harvey; Rachel Hill-Tout; Sebastian S Fuller; Elisabeth J Adams; S Tariq Sadiq
Journal:  BMJ Open       Date:  2018-09-10       Impact factor: 2.692

10.  Correlation Between Bladder Pain Syndrome/Interstitial Cystitis and Pelvic Inflammatory Disease.

Authors:  Shiu-Dong Chung; Chao-Hsiang Chang; Peir-Haur Hung; Chi-Jung Chung; Chih-Hsin Muo; Chao-Yuan Huang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.